What is Personalis?
Founded in 2011 and headquartered in Menlo Park, California, Personalis provides sophisticated genomic sequencing and analytic solutions. The company's core mission is to support the development of personalized cancer vaccines and other cancer immunotherapies. By leveraging cutting-edge technology, Personalis aims to revolutionize cancer treatment by enabling highly tailored therapeutic strategies based on individual patient genomic profiles. Their work is critical in the evolving landscape of precision medicine, offering advanced tools for researchers and clinicians.
How much funding has Personalis raised?
Personalis has raised a total of $233.5M across 5 funding rounds:
Series A
$20M
Series B
$22M
Series C
$33M
Stock Offering
$140.8M
Stock Offering
$17.7M
Series A (2011): $20M with participation from Stanford University, Mohr Davidow Ventures, Abingworth, and Lightspeed Venture Partners
Series B (2013): $22M led by Wellington Shields & Co., Mohr Davidow Ventures, Abingworth, and Lightspeed Venture Partners
Series C (2015): $33M supported by Abingworth, Lightspeed Venture Partners, and Mohr Davidow Ventures
Stock Issuance/Offering (2019): $140.8M, investors not publicly disclosed
Stock Issuance/Offering (2024): $17.7M backed by Tempus
Key Investors in Personalis
Tempus
Tempus is an entity focused on leveraging AI in healthcare to advance precision medicine, deriving insights from extensive clinical and molecular data to enable data-driven decisions for personalized care and targeted therapies.
Abingworth
Abingworth is a transatlantic life sciences investment firm that provides capital and expertise to transform cutting-edge science into novel medicines, focusing on seed, development, and clinical co-development stages.
Lightspeed Venture Partners
Lightspeed Venture Partners (lsvp.com) is a global multistage venture capital firm investing in early and growth-stage technology companies across various sectors, including enterprise software and healthcare.
What's next for Personalis?
The recent major strategic investment positions Personalis for accelerated growth and further innovation in the competitive biotech sector. This capital infusion is expected to bolster the company's research and development efforts, potentially expanding its service offerings and market reach. With a clear focus on personalized cancer therapies, Personalis is poised to make significant contributions to oncology, driving forward the development of next-generation treatments and solidifying its position as a key player in genomic analytics.
See full Personalis company page
